# Achieve Life Sciences Inc. (ACHV) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.49, market value $874 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Achieve Life Sciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.

## Profitability
- **Return on equity: -254.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -39.2%**. Each dollar of assets produces -39.2% of profit.

## Growth
- **EPS growth (1 yr): -0.8%**. Earnings per share fell 0.8%.

## Financial health
- **Current ratio: 4.39** (quick 4.39). Current assets cover the next year's liabilities 4.39 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Achieve Life Sciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Achieve Life Sciences Inc.; the consensus is strong_buy, with an average price target of $13.83 (+63% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 204.3%** (YTD 70.8%, 3-mo 65.5%). The shares are up 204.3% over twelve months including dividends.
- **From 52-week high: -1.7%** (224.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): 1.85** (volatility 90%). Beta of 1.85 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ACHV · Page: https://foliofundamentals.com/stocks/achv

Not investment advice.